Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ on osteoarthritis knee injections

This article was originally published in The Gray Sheet

Executive Summary

Despite broad use, hyaluronic acid-based injections to treat osteoarthritis in the knee are not backed by high quality evidence of benefit, concludes the Agency for Healthcare Research and Quality in a 1report released Oct. 4. Existing trials "generally show positive effects" of the treatments on pain and function scores compared with placebo, and the relative risk appears to be low, but results are undermined by "variable trial quality, potential publication bias, and unclear clinical significance of the changes reported," AHRQ writes. The agency says a rigorous, randomized controlled trial is still needed. PMA-approved injections include Hyalgan (Sanofi-Aventis), Synvisc (Genzyme), Supartz (Smith & Nephew), Orthovisc (Anika Therapeutics) and Euflexxa (Ferring Pharmaceuticals)
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT025324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel